GeneFerm Biotechnology Return On Equity vs. Current Valuation
| 1796 Stock | TWD 46.25 1.35 2.84% |
For GeneFerm Biotechnology profitability analysis, we use financial ratios and fundamental drivers that measure the ability of GeneFerm Biotechnology to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well GeneFerm Biotechnology Co utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between GeneFerm Biotechnology's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of GeneFerm Biotechnology Co over time as well as its relative position and ranking within its peers.
GeneFerm |
GeneFerm Biotechnology Current Valuation vs. Return On Equity Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining GeneFerm Biotechnology's current stock value. Our valuation model uses many indicators to compare GeneFerm Biotechnology value to that of its competitors to determine the firm's financial worth. GeneFerm Biotechnology Co is rated fourth in return on equity category among its peers. It is rated below average in current valuation category among its peers reporting about 20,489,917,424 of Current Valuation per Return On Equity. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the GeneFerm Biotechnology's earnings, one of the primary drivers of an investment's value.GeneFerm Current Valuation vs. Return On Equity
Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
GeneFerm Biotechnology |
| = | 0.12 |
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
GeneFerm Biotechnology |
| = | 2.48 B |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
GeneFerm Current Valuation vs Competition
GeneFerm Biotechnology Co is rated below average in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Drug Manufacturers—Specialty & Generic industry is presently estimated at about 30.63 Billion. GeneFerm Biotechnology holds roughly 2.48 Billion in current valuation claiming about 8% of equities under Drug Manufacturers—Specialty & Generic industry.
GeneFerm Biotechnology Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in GeneFerm Biotechnology, profitability is also one of the essential criteria for including it into their portfolios because, without profit, GeneFerm Biotechnology will eventually generate negative long term returns. The profitability progress is the general direction of GeneFerm Biotechnology's change in net profit over the period of time. It can combine multiple indicators of GeneFerm Biotechnology, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
GeneFerm Biotechnology Co., Ltd. develops, manufactures, markets, and sells fermented products in Taiwan and internationally. The company was founded in 1999 and is based in Taipei City, Taiwan. GENEFERM BIOTECHNOLOGY operates under Drug ManufacturersSpecialty Generic classification in Taiwan and is traded on Taiwan OTC Exchange.
GeneFerm Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on GeneFerm Biotechnology. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of GeneFerm Biotechnology position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the GeneFerm Biotechnology's important profitability drivers and their relationship over time.
Use GeneFerm Biotechnology in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if GeneFerm Biotechnology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in GeneFerm Biotechnology will appreciate offsetting losses from the drop in the long position's value.GeneFerm Biotechnology Pair Trading
GeneFerm Biotechnology Co Pair Trading Analysis
The ability to find closely correlated positions to GeneFerm Biotechnology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace GeneFerm Biotechnology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back GeneFerm Biotechnology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling GeneFerm Biotechnology Co to buy it.
The correlation of GeneFerm Biotechnology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as GeneFerm Biotechnology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if GeneFerm Biotechnology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for GeneFerm Biotechnology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your GeneFerm Biotechnology position
In addition to having GeneFerm Biotechnology in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Latest Gainers Thematic Idea Now
Latest Gainers
Dynamically computed list of top equities currently sorted across major exchanges. The Latest Gainers theme has 0 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Latest Gainers Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for GeneFerm Stock Analysis
When running GeneFerm Biotechnology's price analysis, check to measure GeneFerm Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GeneFerm Biotechnology is operating at the current time. Most of GeneFerm Biotechnology's value examination focuses on studying past and present price action to predict the probability of GeneFerm Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GeneFerm Biotechnology's price. Additionally, you may evaluate how the addition of GeneFerm Biotechnology to your portfolios can decrease your overall portfolio volatility.